hase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia | Aplastic Anemia and MDS International Foundation
  1. Treatments
  2. Clinical Trials

Clinical Trial: NCT02381548

hase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
https://clinicaltrials.gov/ct2/show/NCT02381548
Purpose: 

This phase I trial studies the side effects and best dose of WEE1 inhibitor AZD1775 and belinostat when given together in treating patients with myeloid malignancies that have returned after a period of improvement or have not responded to previous treatment or patients with untreated acute myeloid leukemia. WEE1 inhibitor AZD1775 and belinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Status: 
Recruiting
Study Date: 
Sat, 08/01/2015 to Thu, 10/01/2015
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Belinostat Given IV Other Names: Beleodaq PXD 101 PXD101 Other: Laboratory Biomarker Analysis Correlative studies Other: Pharmacological Study Correlative studies Drug: WEE1 Inhibitor AZD1775 Given PO Other Names: AZD-1775 AZD1775 MK-1775 MK1775